These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 36633259)

  • 1. Checkpoint inhibitor hepatotoxicity: pathogenesis and management.
    Cunningham M; Gupta R; Butler M
    Hepatology; 2024 Jan; 79(1):198-212. PubMed ID: 36633259
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatotoxicity induced by immune checkpoint inhibitors: a comprehensive review including current and alternative management strategies.
    Jennings JJ; Mandaliya R; Nakshabandi A; Lewis JH
    Expert Opin Drug Metab Toxicol; 2019 Mar; 15(3):231-244. PubMed ID: 30677306
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mycophenolate mofetil for immune checkpoint inhibitor-related hepatotoxicity relapsing during dose reduction of corticosteroid: A report of two cases and literature review.
    Ueno M; Takabatake H; Hata A; Kayahara T; Morimoto Y; Notohara K; Mizuno M
    Cancer Rep (Hoboken); 2022 Sep; 5(9):e1624. PubMed ID: 35575047
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hepatotoxicity of immune checkpoint inhibitors: An evolving picture of risk associated with a vital class of immunotherapy agents.
    Suzman DL; Pelosof L; Rosenberg A; Avigan MI
    Liver Int; 2018 Jun; 38(6):976-987. PubMed ID: 29603856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitors-Induced Hepatitis.
    Tian Y; Abu-Sbeih H; Wang Y
    Adv Exp Med Biol; 2018; 995():159-164. PubMed ID: 30539511
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatotoxicity From Immune Checkpoint Inhibitors: A Systematic Review and Management Recommendation.
    Peeraphatdit TB; Wang J; Odenwald MA; Hu S; Hart J; Charlton MR
    Hepatology; 2020 Jul; 72(1):315-329. PubMed ID: 32167613
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatobiliary and Pancreatic Adverse Events.
    Zhang HC; Wang LS; Miller E
    Adv Exp Med Biol; 2021; 1342():339-355. PubMed ID: 34972973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of autoimmune and viral hepatitis in immunotherapy: a narrative review.
    Kuo L; Kuwelker S; Tsai E
    Ann Palliat Med; 2023 Nov; 12(6):1275-1294. PubMed ID: 37731304
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatobiliary Adverse Events.
    Abu-Sbeih H; Wang Y
    Adv Exp Med Biol; 2020; 1244():271-276. PubMed ID: 32301021
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Characteristics and Adverse Impact of Hepatotoxicity due to Immune Checkpoint Inhibitors.
    Miller ED; Abu-Sbeih H; Styskel B; Nogueras Gonzalez GM; Blechacz B; Naing A; Chalasani N
    Am J Gastroenterol; 2020 Feb; 115(2):251-261. PubMed ID: 31789632
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diagnosis and management of immune mediated liver injury from checkpoint inhibitors.
    Likhitsup A; Fontana RJ
    Curr Opin Gastroenterol; 2024 May; 40(3):164-171. PubMed ID: 38375823
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes after resumption of immune checkpoint inhibitor therapy after high-grade immune-mediated hepatitis.
    Li M; Sack JS; Rahma OE; Hodi FS; Zucker SD; Grover S
    Cancer; 2020 Dec; 126(23):5088-5097. PubMed ID: 32888341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Diagnosis and Management of Hepatitis in Patients on Checkpoint Blockade.
    Reynolds K; Thomas M; Dougan M
    Oncologist; 2018 Sep; 23(9):991-997. PubMed ID: 29853659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hepatic immune-mediatedadverseeffects of immune checkpoint inhibitors: analysis of real-life experience.
    da Silva JA; Falcão D; Cardoso C; Pires AL; Araújo A; Castro-Poças F
    Ann Hepatol; 2021 Dec; 26():100561. PubMed ID: 34653687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatotoxicity Associated with Immune Checkpoint Inhibitors in Clinical Practice: A Study Leveraging Data from the US Food and Drug Administration's Adverse Event Reporting System.
    Wang H; Yang H; Zhou X; Zhang X
    Clin Ther; 2023 Feb; 45(2):151-159. PubMed ID: 36682994
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of liver enzyme elevations and hepatotoxicity in patients treated with checkpoint inhibitor immunotherapy.
    Cunningham M; Iafolla M; Kanjanapan Y; Cerocchi O; Butler M; Siu LL; Bedard PL; Ross K; Hansen B; Spreafico A; Feld JJ
    PLoS One; 2021; 16(6):e0253070. PubMed ID: 34115819
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Management of immune checkpoint inhibitors-induced liver toxicity in cancer].
    Lebossé F; Bancel B; Levrero M; Merle P
    Bull Cancer; 2020 Oct; 107(10):1056-1068. PubMed ID: 32951849
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Time from immune checkpoint inhibitor to sotorasib use correlates with risk of hepatotoxicity in non-small cell lung cancer: A brief report.
    Desai A; Rakshit S; Bansal R; Ashara Y; Potter A; Manochakian R; Lou Y; Zhao Y; Ernani V; Savvides P; Schwecke A; Moffett N; Hocum C; Leventakos K; Adjei A; Marks R; Molina J; Mansfield AS; Chen ZM; Dimou A
    Cancer Treat Res Commun; 2023; 36():100743. PubMed ID: 37531736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment strategy for myocarditis in patients using immune checkpoint inhibitors or combined anti-vascular endothelial growth factor therapy by clinical severity.
    Liu Q; Yu Y; Lin J; Wang Y; Ai L; Li Q; Wu W; Jin H; Li S; Liu M; Yu S; Liu T
    Eur J Cancer; 2021 Nov; 157():10-20. PubMed ID: 34464781
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Corticosteroids and Cancer Immunotherapy.
    Goodman RS; Johnson DB; Balko JM
    Clin Cancer Res; 2023 Jul; 29(14):2580-2587. PubMed ID: 36648402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.